Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArgent Bio. Regulatory News (RGT)

  • There is currently no data for RGT

Director/PDMR Shareholding

15 Oct 2024 08:54

RNS Number : 2252I
Argent Biopharma Limited
15 October 2024
 

 

15 October 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

PDMR Notification

 

Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), advises of the following transaction which took place on 15 October 2024 whereby, Roby Zomer (Argent BioPharma's Managing Director & CEO) was issued 4,000,000 fully paid ordinary shares in Company at a price of A$0.41 each following the approval of resolution 1 at a general meeting of shareholders on 1 October 2024.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Roby Zomer

2

Reason for the notification

 

(a)

Position

 

Managing Director and Chief Executive Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Full name of entity

Argent BioPharma Ltd

 

Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU0000326647

(c)

Nature of transaction

Shares issued in accordance with the passing of resolution 1 at a general meeting held 1 October 2024.

(d)

Currency

Price

Volume

Total

AUD

0.41

4,000,000

$1,640,000

Aggregated information

AUD

0.41

4,000,000

$1,640,000

(e)

Date of transaction

 

15 October 2024

(f)

Place of transaction

 

Outside a trading venue

 

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma Limited

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

 

Argent BioPharma Limited

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGRBDGBUBDGSU
Date   Source Headline
29th Nov 20247:00 amRNSASX & LSE Listing Update
28th Nov 20249:09 amRNSResult of AGM
31st Oct 20247:00 amRNSSeptember 2024 Quarterly Report
25th Oct 20247:13 amRNSDispatch of Annual General Meeting Documents
24th Oct 20247:24 amRNSPlacing to Raise A$200,000
15th Oct 20248:56 amRNSHolding(s) in Company
15th Oct 20248:54 amRNSDirector/PDMR Shareholding
9th Oct 20247:00 amRNSRefinancing of Convertible Security Agreement
1st Oct 202410:33 amRNSResult of Meeting
30th Sep 20249:34 amRNSAnnual Report for the year ended 30 June 2024
25th Sep 20247:50 amRNSDate of AGM & Closing Date of Director Nominations
23rd Sep 20247:24 amRNSASX Delisting Update
12th Sep 20247:00 amRNSDirector/PDMR Shareholding
6th Sep 20247:00 amRNSCompany Presentation
30th Aug 20247:10 amRNS30 June 2024 Preliminary Financial Report
27th Aug 20247:05 amRNSLetter from the CEO
27th Aug 20247:00 amRNSNotice of General Meeting
21st Aug 20247:00 amRNSSINTEF Collaboration for Chronic Wound Management
15th Aug 20247:20 amRNSVoluntary Delisting From ASX
30th Jul 20248:00 amRNSJune 2024 Quarter Activity Report and Cash Flow
16th Jul 20249:58 amRNSPlacing to Raise US$2,000,000
1st Jul 20247:02 amRNSCompany Presentation
1st Jul 20247:00 amRNSPlacing to Raise US$500,000
21st Jun 20247:00 amRNSAppointment of UK Corporate Broker
23rd May 20248:00 amRNSChange of OTCQB Company Code
7th May 20247:00 amRNSTrading on the OTCQB and Appointment of CFO
30th Apr 20244:01 pmRNSPDMR Notification
30th Apr 20248:54 amRNSMarch 2024 Quarter Activity Report
15th Apr 20247:00 amRNSDr. Shlomo Sadoun Joins Advisory Board
10th Apr 20244:30 pmRNSPDMR Notification

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.